Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: Structural insights, chemical diversity and molecular evolution

Future Medicinal Chemistry

Volumn 4, Issue 3, 2012, Pages 315-328

  Jin, Meizhong ^a   Wang, Jing ^a   Buck, Elizabeth ^a   Mulvihill, Mark J ^a  

^a OSI PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; BMS 536924; BMS 695735; BMS 754807; GSK 1838705A; GSK 1904529A; IMIDAZOPYRAZINE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; INSULIN RECEPTOR; ISOQUINOLINE DERIVATIVE; LINSITINIB; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BODY WEIGHT; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL MODIFICATION; COLON CANCER; CRYSTAL STRUCTURE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SMALL MOLECULE LIBRARIES;

EID: 84863239500     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.180     Document Type: Review

References (64)

1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-928 (2008). Provides an overview of insulin and insulin-like growth factor signaling in neoplasia with a focus on recent findings relevant to cancer biology.
2. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 195, 127-137 (2003).
3. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-1) and type 1 IGF receptor (IGF1r). Cell 75, 59-72 (1993).
4. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl Acad. Sci. USA 90, 11217-11221 (1993).
5. Maloney EK, McLaughlin JL, Dagdigian NE et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 63, 5073-5083 (2003).
6. Garcia-Echeverria C, Pearson MA, Marti A et al. In vivo antitumor activity of NVP-AEW541 - a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5, 231-239 (2004).
7. Cohen BD, Baker DA, Soderstrom C et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 11, 2063-2073 (2005).
8. Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr. Opin. Pharmacol. 8, 384-392 (2008).
9. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell. Mol. Life Sci. 57, 1050-1093 (2000).
10. Cui H, Cruz-Correa M, Giardiello FM et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299, 1753-1755 (2003).
11. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP. Relaxation of imprinted genes in human cancer. Nature 362, 747-749 (1993).
12. Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat. Genet. 7, 433-439 (1994).
13. Giordano TJ, Kuick R, Else T et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 15, 668-676 (2009).
14. Frittitta L, Vigneri R, Stampfer MR, Goldfine ID. Insulin receptor overexpression in 184B5 human mammary epithelial cells induces a ligand-dependent transformed phenotype. J. Cell Biochem. 57, 666-669 (1995).
15. Giorgino F, Belfiore A, Milazzo G et al. Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand- mediated transformed phenotype. Mol. Endocrinol. 5, 452-459 (1991).
16. Louvi A, Accili D, Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev. Biol. 189, 33-48 (1997).
17. Sciacca L, Costantino A, Pandini G et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 18, 2471-2479 (1999).
18. Morrione A, Valentinis B, Xu SQ et al. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc. Natl Acad. Sci. USA 94, 3777-3782 (1997).
19. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA. Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 143, 3259-3267 (2002).
20. Vella V, Pandini G, Sciacca L et al. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J. Clin. Endocrinol. Metab. 87, 245-254 (2002). Studies compensatory crosstalk between IGF-1R and insulin receptor (IR) and provides rationale for co-targeting IGF-1R and IR in cancer treatment.
21. Buck E, Gokhale PC, Koujak S et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 9, 2652-2664 (2010).
22. Haluska P, Shaw HM, Batzel GN et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res. 13, 5834-5840 (2007).
23. Iwasa T, Okamoto I, Suzuki M et al. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin. Cancer Res. 15, 5117-5125 (2009).
24. Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 26, 2423-2434 (2007).
25. Allen GW, Saba C, Armstrong EA et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res. 67, 1155-1162 (2007).
26. Miglietta A, Panno ML, Bozzo F, Gabriel L, Bocca C. Insulin can modulate MCF-7 cell response to paclitaxel. Cancer Lett. 209, 139-145 (2004).
27. Martins AS, Mackintosh C, Martin DH et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin. Cancer Res. 12, 3532-3540 (2006).
28. Zeng X, Sachdev D, Zhang H, Gaillard-Kelly M, Yee D. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin. Cancer Res. 15, 2840-2849 (2009).
29. Huang GS, Brouwer-Visser J, Ramirez MJ et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin. Cancer. Res. 16, 2999-3010 (2010).
30. Guix M, Faber AC, Wang SE et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118, 2609-2619 (2008).
31. Buck E, Eyzaguirre A, Rosenfeld-Franklin M et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 68, 8322-8332 (2008).
32. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62, 200-207 (2002).
33. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ et al. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int. J. Cancer 119, 2557-2566 (2006).
34. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 66, 10100-10111 (2006).
35. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
36. Alami N, Page V, Yu Q et al. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm. IGF Res. 18, 487-496 (2008).
37. Jerome L, Alami N, Belanger S et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res. 66, 7245-7252 (2006).
38. Gualberto A. Figitumumab (CP-751,871) for cancer therapy. Expert Opin. Biol. Ther. 10, 575-585 (2010).
39. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28, 3009-3021 (2009).
40. Leong S, Gore L, Benjamin R, Warren TL, Eckhardt SG, Camidge DR. A Phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors. Presented at: The AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Discovery, Biology, and Clinical Applications San Francisco, CA, USA, 22-26 October 2007.
41. Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr. Opin. Mol. Ther. 12, 361-371 (2010).
42. Mulvihill MJ, Buck E. The discovery of OSI-906, a small-molecule inhibitor of the insulin-like growth factor-1 and insulin receptors. Royal Soc. Chem. Drug Discov. Series No. 2 (In press) (2011). Describes the discovery of OSI-906, the most advanced dual IGF-1R and IR inhibitor currently in clinical evaluation (Phase III).
43. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 1, 1153-1171 (2009).
44. Carboni JM, Wittman M, Yang Z et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 8, 3341-3349 (2009).
45. Ji Q, Mulvihill MJ, Rosenfeld-Franklin M et al. A novel, potent and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol. Cancer Ther. 6, 2158-2167 (2007).
46. Wittman M, Velaparthi U, Vyas D. Recent progress in the development of small molecule inhibitors of insulin-like growth factor-I receptor kinase. Ann. Reports Med. Chem. 44, 281-299 (2009).
47. Li R, Pourpak A, Morris SW. Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J. Med. Chem. 52, 4981-5004 (2009).
48. Wittman D, Carboni J, Attar R et al. Discovery of a 1H-benzoimidazol-2- yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity, J. Med. Chem. 48, 5639-5643 (2005).
49. Velaparthi U, Wittman M, Liu P et al. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl) piperidin-4-yl)-4-methyl-1Hbenzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity. J. Med. Chem. 51, 5897-5900 (2008). Describes the discovery of BMS-754807, a dual IGF-1R and IR inhibitor currently in Phase I clinical evaluation.
50. Wittman D, Carboni J, Yang Z et al. Discovery of a 2,4-disubstituted pyrrolo-[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development, J. Med. Chem. 52, 7360-7363 (2009).
51. Chamberlain SD, Redman AM, Wilson JW et al. Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. Bioorg. Med. Chem. Lett. 19, 360-364 (2009).
52. Chamberlain SD, Wilson JW, Deanda F et al. Discovery of 4,6-bis-anilino-1Hpyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase. Bioorg. Med. Chem. Lett. 19, 469-473 (2009).
53. Sabbatini P, Korenchuk S, Rowand J et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 8, 2811-2820 (2009).
54. Chamberlain SD, Redman AM, Patnaik S et al. Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway. Bioorg. Med. Chem. Lett. 19, 373-377 (2009).
55. Patnaik S, Stevens K, Gerding R et al. Discovery of 3,5-disubstituted-1H- pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase. Bioorg. Med. Chem. Lett. 19, 3136-3140 (2009).
56. Liu Y, Gray N. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358 (2006).
57. Emmitte K, Wilson B, Baum E et al. Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R). Bioorg. Med. Chem. Lett. 19, 1004-1008 (2009).
58. Sabbatini P, Rowand J, Groy A et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin. Cancer Res. 15, 3058-3067 (2009).
59. Mayer C, Banker L, Boschelli F et al. Lead identification to generate isoquinolinedione inhibitors of insulin like growth factor receptor (IGF-1R) for potential use in cancer treatment. Bioorg. Med. Chem. Lett. 18, 3641-3645 (2008).
60. Miller L, Mayer S, Berger D et al. Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment. Bioorg. Med. Chem. Lett. 19, 62-66 (2009).
61. Mulvihill M, Ji Q, Coate H et al. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. Bioorg. Med. Chem. 16, 1359-1375 (2008).
62. Karaman W, Herrgard S, Treiber K et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
63. Jin M, Gokhale P, Cooke A et al. Discovery of an orally efficacious imidazo[5,1-f][1,2,4]triazine dual inhibitor of IGF-1R and IR. ACS Med. Chem. Lett. 1, 510-515 (2010). Compound 9 in this manuscript is referred to as FQIT (cis-3-[4-amino-5-(8-fluoro-2-phenyl-quinolin-7-yl)-imidazo[5,1-f][1,2,4] triazin-7-yl]-1-methyl-cyclobutanol).
64. Jin M, Kleinberg A, Cooke A et al. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy. Bioorg. Med. Chem. Lett. 21, 1176-1180 (2011).